Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

The obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in ...

The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.